PAVmed's Veris Health Secures $1.8 Million NIH Funding for Cancer Care
PAVmed's Veris Health Secures $1.8 Million NIH Funding for Cancer Care
PAVmed Inc. (NASDAQ: PAVM) has announced an exciting development regarding its subsidiary, Veris Health Inc. Recently, Veris Health was awarded a significant grant of $1.8 million from the National Institute on Minority Health and Health Disparities (NIMHD), a component of the National Institutes of Health (NIH). This grant is a crucial step towards enhancing the Veris Cancer Care Platform, which is designed to support medically underserved cancer patients.
Understanding the Grant's Purpose
The awarded grant will be instrumental in researching how the Veris Cancer Care Platform can be optimized for patients who often face numerous barriers in accessing adequate cancer care. These barriers can include language differences, limited access to technology, and critical socioeconomic challenges. The project is notably titled "Bridging the Gap: Enhancing Cancer Care for Underserved Populations with the Veris Health Cancer Care Platform" and will be developed in collaboration with an academic cancer center.
Statements from Key Personnel
James D. Mitchell M.D., who serves as the Vice President of Digital Health at PAVmed and Chief Medical Officer at Veris, expressed gratitude at receiving this prestigious NIH grant. He noted that it underscores the platform’s potential in enhancing cancer care. According to Dr. Mitchell, this grant will empower them to broaden the reach and efficacy of their technology while fostering stronger connections with academic centers and the oncology community. He emphasized their dedication to leveraging this technology to benefit a wider and more diverse range of patients, ultimately improving healthcare outcomes and accessibility.
The Importance of the Grant for Veris
In a similar vein, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, highlighted the significance of the NIH grant for Veris. He remarked that it represents crucial non-dilutive funding at a pivotal moment for the company. Veris is looking to advance its commercial strategy, including the regulatory approval and launch of its innovative implantable physiological monitor. The goal is for Veris to attain independent financeability while leveraging PAVmed's shared resources.
About the Veris Cancer Care Platform
Veris Health is particularly known for its flagship product, the Veris Cancer Care Platform. This comprehensive digital health solution integrates various features, including remote physiological data collection, symptom reporting, telehealth functionality, and integration with electronic health records. The primary aim is to enhance personalized cancer care, enabling early detection of complications and minimizing unnecessary hospitalizations.
How the Platform Works
Cancer patients utilizing the Veris platform receive a VerisBox™, a set of connected health devices that send physiological data to a cloud-based clinician portal through an embedded cellular connection. Additionally, patients have access to a dedicated app that allows them to report symptoms and general well-being to their healthcare team. Notably, this app encourages users to include caretakers and family members in their cancer care journey.
Future Developments and Innovations
As part of its ongoing commitment to innovation, Veris is developing an implantable physiological monitor that can integrate seamlessly with the Veris Cancer Care Platform. This implantable device aims to provide consistent physiologic data, significantly enhancing both clinical and commercial prospects for the platform.
About PAVmed and Its Vision
PAVmed Inc. stands out as a diversified medical technology enterprise actively involved in medical devices, diagnostics, and digital health. Alongside Veris Health, PAVmed is advancing its initiatives, including Lucid Diagnostics, which focuses on early detection tools for esophageal cancer.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Veris Health?
The NIH grant aims to enhance the Veris Cancer Care Platform to better serve medically underserved populations by addressing their unique challenges in accessing cancer care.
Who are the key individuals involved in this project?
James D. Mitchell M.D. is the Vice President of Digital Health and Chief Medical Officer at Veris, while Lishan Aklog, M.D. is the Chairman and CEO of PAVmed.
What does the Veris Cancer Care Platform offer?
The platform provides remote patient monitoring, symptom reporting, telehealth capabilities, and integrates electronic health records to enhance patient care.
How does the Veris platform improve cancer care?
By using connected devices and mobile applications, the platform facilitates early detection of complications and enhances patient-provider communication.
What is the significance of the implantable physiological monitor?
This monitor is designed to provide continuous physiologic data, thereby improving treatment and monitoring of cancer patients.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Revolutionizing Patient Care: Time Savings with Sunoh.ai
- Earnings Momentum: Key Insights for Upcoming Reports
- Insightful Study Reveals Drug Pricing Challenges for Seniors
- KOSPET Launches Stylish Wearables for Adventurers and Trendsetters
- Starboard Value Pushes for Investigation into Pfizer's Leadership
- Revolutionizing Cancer Diagnostics: Paige Alba's Debut at HLTH
- Zoovu Partners with Microsoft Azure for Enhanced Product Discovery
- Forcura Secures Prestigious HITRUST r2 Certification Again
- Key Highlights and Insights for Global Alts Miami 2025 Event
- Leveraging Servo Motors for Advanced Automation Solutions
Recent Articles
- SensiML Enhances IoT Development with RISC-V Processor Support
- WellStat's New Leadership Team Set to Drive Innovative Growth
- Connexa Sports Technologies Advances with Major Licensing Deal
- IV Bags Industry Insights: Shaping Future Market Growth
- Baird Confirms Outperform Rating for Costco Amidst Strong Growth
- Exploring the Rising Demand in the Taste Masking Industry
- Air India's Bold Move: 85 New Airbus Jets and Future Plans
- The Rise of Bio-based Acrylonitrile: Future Insights and Trends
- E2open's Steady Q2 Performance & Growth Endeavors Ahead
- BUIDL(NEW): A Revolutionary Launchpad Now on CoinW Platform
- Intrusion Inc. Thrives with 50% Revenue Surge from Shield Product
- Leadership Changes Spark New Era for Vireo Growth Inc.
- Applied Digital Achieves Remarkable 67% Revenue Growth
- Beamr Imaging Ltd. Engages at Demuxed 2024 as Bronze Sponsor
- Builders FirstSource Gains as Goldman Sachs Rates Stock 'Buy'
- Yuanyu Partners to Capture $4 Billion Dating Market Growth
- ZenaTech Unveils Innovative IQ Nano Drone for Enhanced Efficiency
- Innovative Tri-Specific Antibody Platform by Purple Biotech
- Valour Sui ETP Launch: A Gateway to Blockchain Investment
- Theratechnologies Reports Impressive Q3 Growth in 2024
- Zevra Therapeutics Engages in Vital Discussions on Rare Diseases
- Brixton Metals Unveils Promising Gold Find at Trapper Target
- Exploring Kinder Morgan's Impressive Dividend Strategy
- Delta Air Lines Navigates Challenges Amid Q3 Earnings Decline
- Opthea Showcases Innovative Wet AMD Research at Renowned Event
- Immatics Secures $150 Million Public Offering to Advance Cancer Treatments
- Intellia Therapeutics Reschedules Key Investor Webcast
- NexGold and Signal Gold Merger: A New Era in Gold Development
- Founders Metals Secures Strategic Investment and Financing
- Alliance Witan PLC Welcomes New Board Directors for Growth
- QIAGEN N.V. Announces Q3 2024 Results Webcast Schedule
- Core42 Revolutionizes AI Cloud Solutions with NVIDIA GPUs
- Lineage Inc. Announces Third-Quarter 2024 Financial Call Details
- Innovative Space Project Aims to Enhance Orbital Monitoring
- Owens Corning Excels as a Top Corporate Citizen for 2024
- Top Materials Stocks with High Dividends for Smart Investors
- USANA's Non-GMO Products Gain Trusted Recognition Online
- Natural Grocers Grand Reopening Event to Delight Customers Soon
- Inflammatix Strengthens Leadership Team with New Executives
- Reklaim Ltd Achieves 11% Debt Reduction to Strengthen Growth
- SensiML Enhances AI Development with RISC-V Integration
- Stagwell to Host Webcast on Upcoming Financial Results
- Duchesnay Pharmaceutical Group Expands Global NVP Portfolio
- FERMWORX Secures Department of Defense Contract for Bioindustrial Growth
- CB&I Secures Major Contract for Perdaman Chemicals Project
- Barrick Gold Unveils Exciting Q3 2024 Financial Results Plan
- Orion Group Holdings Prepares for Key Financial Announcement
- Tempest Partners with Roche for Liver Cancer Therapy Trial
- Zapp EV Collaborates with AIH Group for New Manufacturing Hub
- China's Ambitious $24B Investment in Coal-to-Oil Technology